Señales en vivo de BANB.SW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 10:01):

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide...

Stats
Volumen de hoy	18 691.00
Volumen promedio	87 511.00
Capitalización de mercado	6.06B
EPS	CHF0 ( 2024-03-06 )
Próxima fecha de ganancias	( CHF0 ) 2024-07-24
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	53.87
ATR14	CHF0.164 (0.20%)

Volumen Correlación

Largo: -0.16 (neutral)

Corto: 0.76 (moderate)

Signal:(49.542) Neutral

Bachem Holding AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bachem Holding AG Correlación - Moneda/Commodity

0.26
( neutral )

0.78
( moderate )

0.05
( neutral )

0.10
( neutral )

0.32
( neutral )

-0.82
( strong negative )

Bachem Holding AG Finanzas

Annual	2023
Ingresos:	CHF577.32M
Beneficio Bruto:	CHF176.96M (30.65 %)
EPS:	CHF1.500

FY	2023
Ingresos:	CHF577.32M
Beneficio Bruto:	CHF176.96M (30.65 %)
EPS:	CHF1.500

FY	2022
Ingresos:	CHF531.74M
Beneficio Bruto:	CHF171.28M (32.21 %)
EPS:	CHF1.370

FY	2021
Ingresos:	CHF503.23M
Beneficio Bruto:	CHF166.73M (33.13 %)
EPS:	CHF0.287

Financial Reports:

No articles found.

Bachem Holding AG

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.